[en] The hemodynamic effects of flecainide acetate, a new class I antiarrhythmic agent, were studied in 10 patients with coronary heart disease. The drug was injected intravenously at a dose of 2 mg/kg over 30 minutes. The mean drug plasma level achieved was 394 ng/ml (range 329 to 470). The heart rate did not change, but a significant increase (p less than 0.001) in P-R (+17%), QRS (+15%), and Q-T (+7%) duration occurred after drug administration. Negative inotropic effects also were observed and consisted of an increase (p less than 0.01) in pulmonary wedge pressure (+27%) and a decrease (p less than 0.01) in stroke index (-10%), left ventricular stroke work index (-12%), and left ventricular ejection rate (-11%). No significant change in mean aortic pressure or systemic and pulmonary vascular resistance occurred. Left ventriculography performed after drug infusion revealed a significant increase (p less than 0.01) in systolic volume (+9%) and a decrease in ejection fraction (-9%) and mean velocity of circumferential fiber shortening (Vcf) (-13%). A progressive and significant decrease of dP/dt was observed during drug infusion, but 15 minutes after the injection, dP/dt had returned to near basal values. Thus, flecainide acetate has slight, but significant negative inotropic effects, particularly conspicuous during drug infusion. The drug should be administered with caution in patients with poorly compensated heart.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Vandormael, M.
Collignon, P.
Kulbertus, Henri ; Université de Liège - ULiège > Relations académiques et scientifiques (Médecine)
Language :
English
Title :
Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease.
Duff, Roden, Woosley (1980) Abolition of resistant ventricular arrhythmias by twice daily dosing with flecainide (abstr). Circulation 62:III-I81.
Somani (1980) Antiarrhythmic effects of flecainide. Clin Pharmacol Ther 27:464-470.
Hodges, Haugland, Granrud, Asinger, Mikell, Krejci (1981) Flecainide acetate, a new antiarrhythmic agent: dose ranging and efficacy study (abstr). Am J Cardiol 47:482.
Anderson, Stewart, Perry, Van Hamersveld, Johnson, Conard, Chang, Kvam, Pitt (1981) Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 305:473-477.
Seipel, Abendroth, Breithardt (1981) Electrophysiological effects of flecainide R 818 in man (abstr). Eur Heart J 2 A:115.
Granrud, Krejci, Coyne, Hodges (1981) Sustained elimination of ventricular arrhythmias during chronic flecainide dosing (abstr). Circulation 64:IV-316.
Van Hamersveld, Stewart, Johnson, Anderson (1981) Oral flecainide acetate for long term treatment of ventricular arrhythmias in man (abstr). Circulation 64:IV-316.
Welter, Schmid, Kvam (1977) Cardiovascular profile of R 818, flecainide, a new antiarrhythmic (abstr). Fed Proc 36:1003.
Verdouw, Dekers, Conard (1979) Antiarrhythmic and hemodynamic actions of flecainide acetate (R 818) in the ischemic porcine heart. J Cardiovasc Pharmacol 1:473-486.
Hodges, Hoback, Graham, Erlien, Asinger, Mikell (1981) Cardiac function after oral dosing with flecainide acetate (abstr). Clin Pharmacol Ther 29:251.
Ingels, Daughters, Stinson, Alderman (1980) Evaluation of methods of quantitative left ventricular segmental wall motion in man using myocardial markers as a standard. Circulation 61:966-972.
Mullins, Leshin, Miersziak, Aisobrook, Mitchell (1972) Changes in left ventricular function produced by the injection of contrast media. Am Heart J 83:373-381.
Hamby, Aintablian, Wilsoff, Hartstein (1977) Effects of contrast medium on left ventricular pressure and volume with emphasis on coronary artery disease. Am Heart J 93:9-18.
Fischer, Thomson (1978) Contrast media in coronary arteriography: a review. Invest Radiol 13:450-459.
Jewitt (1980) Hemodynamic effects of newer antiarrhythmic drugs. Am Heart J 100:984-989.
Winkle, Anderson, Peters, Meffin, Fowles, Hainson (1978) The hemodynamic effects of intravenous tocainide in patients with heart disease. Circulation 57:787-792.
Harrison, Winkle, Sami, Mason (1980) Encainide: a new and potent antiarrhythmic agent. Am Heart J 100:1046-1054.
Conard, Carlson, Frost, Ober (1979) Human plasma pharmacokinetics of flecainide acetate (R 818), a new antiarrhythmic following single oral and intravenous dose (abstr). Clin Pharmacol Ther 25:218.